Skip to content
Learn More

Media & Events

iBio acquires multiple assets of AI drug discovery partner RubrYc

September 27, 2022

iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics.

Read More
Top